**Supplementary Table 6.** Association of patient and treatment characteristics and the condition ‘POSEIDON group 1 or group 2’.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Term (unit)** | **Estimate** | **Std Error** | **P value** | | **Odds ratio\*** | **Lower 95%** | **Upper 95%** |
| Intercept | 0.8936 | 0.2951 | 0.0026 | |  |  |  |
| Female age (year) | 0.0289 | 0.0055 | <0.0001 | | 1.0293 | 1.0181 | 1.0407 |
| BMI (Kg/m2) | 0.0367 | 0.0071 | <0.0001 | | 1.0374 | 1.0229 | 1.0521 |
| Infertility duration (month) | -4.52e-5 | 0.0005 | 0.9684 | | 0.9999 | 0.9988 | 1.0010 |
| AFC (n) | -0.1727 | 0.0052 | <0.0001 | | 0.8313 | 0.8328 | 0.8500 |
| Primary treatment indication (Female factor) | 0.2429 | 0.0349 | <0.0001 | | 1.49751 | 1.3399 | 1.6736 |
| Stimulation duration (day) | -0.0643 | 0.0218 | 0.0032 | | 0.4330 | 0.2480 | 0.7560 |
| Total gonadotropin dose (IU) | -8.22e-5 | 4.57e-5 | 0.0723 | | 0.5991 | 0.3427 | 1.0473 |
| GnRH antagonist protocol | 0.2518 | 0.0429 | <0.0001 | | 1.65472 | 1.3983 | 1.9582 |
| Gonadotropin [HMG] | 0.3342 | 0.1285 | 0.0093 | | 2.48093 | 1.7759 | 3.4659 |
| Gonadotropin  [rec-FSH+HMG] | 0.1270 | 0.0618 | 0.0401 | | 2.01654 | 1.7673 | 2.3007 |
| Gonadotropin [rec-FSH] | -0.5743 | 0.0625 | <0.0001 | | 0.40305 | 0.2885 | 0.5630 |
| Study Center (1-2) | -0.4768 | 0.1402 | 0.0007 | | 0.25586 | 0.1664 | 0.3930 |
| Study Center (2-3) | 0.8864 | 0.0873 | <0.0001 | | 3.65457 | 3.0434 | 4.3884 |
| Response: POSEIDON groups 1 or 2 =yes  Distribution: binomial  Estimation method: nominal logistic  Number of Parameters: 13  Whole model test: ChiSquare=3156.77; p<0.0001 | | | | BIC: 10697.5  AICc: 10588.8  RSquare: 0.23  Area under the curve ROC curve: 0.82  Lack of fit test: 0.09 | | | |

Study Center (SC) 1: ANDROFERT (Brazil); SC2: Anatolia IVF (Turkey); SC3: My Duc Hospital (Vietnam)

\*Per unit change in regressor (independent variable)

1Odds ratio for female factor vs. no female factor (unexplained or male factor)

2Odds ratio for GnRH antagonist vs. GnRH agonist

3Odds ratio for gonadotropin utilized: HMG vs. rec-FSH

4Odds ratio for gonadotropin utilized: rec-HMG vs. rec-FSH

5Odds ratio for gonadotropin utilized: rec-FSH vs. HMG

6Odds ratio for Study Center 1 vs. Study Center 2

7Odds ratio for Study Center 2 vs. Study Center 3